EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome

Béatrice Desnous iD, Thibault Beretti, Nathan Muller, Julien Neveu, Nathalie Villeneuve, Anne Lépine, Géraldine Daquin, Mathieu Milh iD

Epilepsia Open · 2024-02 · 9 (1) · 397-403

DOI: 10.1002/epi4.12796 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia Open, online erschienen am 15.11.2023. Verfasst von Béatrice Desnous und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Department, Timone Enfant, APHM, Marseille, France. Hauptthemen laut MEDLINE: Cannabidiol, Rett Syndrome, Epilepsy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aim to assess the efficacy and tolerance of cannabidiol as adjunctive therapy for Rett syndrome (RTT) patients with epilepsy. We conducted a longitudinal observational study through a monocentric cohort of 46 patients with RTT. Patients were recruited from March 2020 to October 2022 and were treated with Epidyolex® (cannabidiol, CBD, 100 mg/mL oral solution). In our cohort, 26 patients had associated epilepsy (26/46 [56%]), and 10/26 (38%) were treated with CBD, in combination with clobazam in 50% of cases. The median dose at their last follow‐up was 15 mg/kg/day. The median treatment duration was 13 months (range: 1–32 months). CBD reduced the incidence of seizures in seven out of 10 patients (70%) with one seizure‐free patient, two patients with a reduction of seizures of more than 75%, and four patients with a decrease of more than 50%. No aggravation of symptoms or adverse effects were observed. Only one patient experienced a transitory drooling and somnolence episode at the CBD initiation. Half of the patients showed a reduction in agitation and/or anxiety attacks, and an improvement in spasticity was reported in 4/10 (40%) of patients. CBD appears to have potential therapeutic value for the treatment of drug‐resistant epilepsy in Rett syndrome. CBD is well tolerated and, when used in combination with clobazam, may increase the effectiveness of clobazam alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolRett SyndromeEpilepsyHumansClobazamAnticonvulsantsSeizures

Stichwörter der Autor:innen

Rett syndromecannabidiolpharmacoresistant epilepsy

Substanzen

CannabidiolClobazamAnticonvulsants

Autor:innen und Institutionen

  • Pediatric Neurology Department, Timone Enfant, APHM, Marseille, France.
  • Pediatric Neurology Department, Lenval, Nice, France.
  • Epileptology and Cerebral Rhythmology Department, Timone Adulte, APHM, Marseille, France.

ORCID-Profile: Béatrice Desnous, Mathieu Milh

Zitieren

APA

Desnous, B., Beretti, T., Muller, N., Neveu, J., Villeneuve, N., Lépine, A., Daquin, G., & Milh, M. (2024). Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome. Epilepsia Open, 9(1), 397-403. https://doi.org/10.1002/epi4.12796

Vancouver

Desnous B, Beretti T, Muller N, Neveu J, Villeneuve N, Lépine A, et al. Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome. Epilepsia Open. 2024;9(1):397-403. doi:10.1002/epi4.12796

BibTeX
@article{Desnous2024,
  author = {Desnous, Béatrice and Beretti, Thibault and Muller, Nathan and Neveu, Julien and Villeneuve, Nathalie and Lépine, Anne and Daquin, Géraldine and Milh, Mathieu},
  title = {Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome},
  journal = {Epilepsia Open},
  year = {2024},
  volume = {9},
  number = {1},
  pages = {397--403},
  doi = {10.1002/epi4.12796}
}
Kostenlos starten →